Beth Israel Deaconess Medical Center and Navigenics Partner to Offer Pathology Residents Personalized Genetic Testing

Residency Training Program Incorporates Personal Genomics into Physician
Education
BOSTON & FOSTER CITY, Calif.--(Business Wire)--
Beth Israel Deaconess Medical Center and Navigenics, Inc., a leading personal
genomics company, today announced a collaboration to make personalized genomics
available to doctors in training.

Beth Israel Deaconess Medical Center (BIDMC) has launched the Personalized
Genomics and Next Generation Sequencing Training Program, a series of lectures,
discussions and presentations designed to promote better understanding of
personalized genomics and the next generation sequencing technologies available
to today`s healthcare providers. And, unique to the program, the participants
will be given the opportunity to have their own genomes analyzed through
Navigenics genetic testing services.

"We believe that genetics and genomics will be critical to the future of health
care," said Mark Boguski, M.D., Ph.D. of BIDMC`s Department of Pathology and the
Center for Biomedical Informatics at Harvard Medical School. "Training our
residents on the leading genetic services and technologies will be essential to
this future, and we are excited to be in the vanguard of a growing effort to
incorporate genetics into medical education nationwide."

BIDMC Pathology residents who choose to undergo personalized genetic testing
will receive important insights into their personal genetic health - including
their predisposition for developing health conditions such as type 2 diabetes,
cancer, heart attack, and celiac disease. Working with one of Navigenics`
board-certified genetic counselors, the pathology residents will gain firsthand
experience interpreting genomic information and understanding its correlation
with related personal medical and health information.

Specifically, BIDMC hopes that this experience with personal genomics combined
with the broad educational program will help its medical trainees:

* Understand how personalized genomics might improve the understanding and
management of human health and disease
* Understand standards of scientific evidence applied to gene-disease
associations and different approaches to risk assessment
* Become familiar with the educational and informational resources for
personalized genomics and its potential
* Understand the issues related to the evaluation of direct-to-consumer
genotyping services
* Become familiar with the interpretation of genomic information and its
correlation with related personal medical and health information

"Beth Israel Deaconess Medical Center is a leader in clinical and educational
excellence," noted Jonathan Lord, M.D., Chief Executive Officer of Navigenics.
"With this progressive program they are setting a precedent for genetics
education for the physicians of tomorrow, and we are thrilled to be a part of
this pioneering effort."

ABOUT NAVIGENICS

Navigenics, Inc. is a privately held company based in Foster City, Calif. The
company was founded by David Agus, M.D. and Dietrich Stephan, Ph.D., with the
goal of improving health outcomes in individuals across the population.
Navigenics educates and empowers individuals and their physicians with knowledge
of their genetic predispositions, and then motivates them to act on the
information to prevent the onset of disease, achieve earlier diagnosis,
appropriately manage disease, or otherwise lessen its impact. Navigenics` lead
investors are Kleiner Perkins Caufield and Byers, Sequoia Capital and MDV-Mohr
Davidow Ventures. More information can be found at www.navigenics.com.

ABOUT BETH ISRAEL DEACONESS MEDICAL CENTER

Beth Israel Deaconess Medical Center is a patient care, teaching and research
affiliate of Harvard Medical School and consistently ranks in the top four in
National Institutes of Health funding among independent hospitals nationwide.
BIDMC is a clinical partner of the Joslin Diabetes Center and is a research
partner of the Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital
of the Boston Red Sox. For more information, visit www.bidmc.org.

Navigenics, Inc.
Brenna Sweeney, 650-585-7523
bsweeney@navigenics.com
or
Beth Israel Deaconess Medical Center
Bonnie Prescott, 617-667-7306
bprescott@bidmc.harvard.edu

Copyright Business Wire 2009